EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy

Abhinav V Reddy, Colin S Hill, Shuchi Sehgal, Lei Zheng, Jin He, Daniel A Laheru, Ana De Jesus-Acosta, Joseph M Herman, Jeffrey Meyer, Amol K Narang

Radiation Oncology Journal · 30.06.2022 · 40 (2) · 111-119

DOI: 10.3857/roj.2021.01060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Oncology Journal, erschienen am 30.06.2022. Verfasst von Abhinav V Reddy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center, Baltimore,…. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate the role of pre- and post-stereotactic body radiation therapy (SBRT) neutrophil-to-lymphocyte ratio (NLR) in patients with localized pancreatic cancer treated with anti-PD-1 (programmed cell death protein-1) antibody and SBRT.Materials and Methods: This was a retrospective review of 68 patients with borderline resectable or locally advanced pancreatic cancer treated with anti-PD-1 antibody and SBRT after multi-agent chemotherapy. Immunotherapy was administered with 5-fraction SBRT in the neoadjuvant, concurrent, or adjuvant/maintenance setting. Clinical outcomes included overall survival (OS), local progression-free survival, distant metastasis-free survival, and progression-free survival. Median pre- and post-SBRT peripheral blood markers were compared with the Mann-Whitney U test. Univariate and multivariable analyses (UVA and MVA) were performed to identify variables associated with clinical outcomes. Linear regression was performed to determine correlations between variables and peripheral blood markers.

Results

A total of 68 patients were included in the study. The percent change between median pre- and post-SBRT absolute lymphocyte count (ALC), absolute neutrophil count, and NLR were -36.0% (p < 0.001), -5.6% (p = 0.190), and +35.7% (p = 0.003), respectively. Median OS after SBRT was 22.4 months. On UVA, pre-SBRT CA19-9 (hazard ratio [HR] = 1.001; 95% confidence interval [CI], 1.000–1.001; p = 0.031), post-SBRT ALC (HR = 0.33; 95% CI, 0.11–0.91; p = 0.031), and post-SBRT NLR (HR = 1.13; 95% CI, 1.04–1.22; p = 0.009) were associated with OS. On MVA, induction chemotherapy duration (HR = 0.75; 95% CI, 0.57–0.99; p = 0.048) and post-SBRT NLR (HR = 1.14; 95% CI, 1.04–1.23; p = 0.002) predicted for OS. Patients with post-SBRT NLR ≥3.2 had a median OS of 15.6 months versus 27.6 months in patients with post-SBRT NLR

Schlagwörter

Stichwörter der Autor:innen

Immune checkpoint inhibitorImmunotherapyLymphocyteNeutrophilPD-1 inhibitorPancreatic cancerStereotactic body radiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center, Baltimore, MD, USA.
  • Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center, Baltimore, MD, USA.
  • Department of Surgery, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center, Baltimore, MD, USA.
  • Department of Radiation Oncology, Northwell Health, New Hyde Park, NY, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Reddy, A. V., Hill, C. S., Sehgal, S., Zheng, L., He, J., Laheru, D. A., Jesus-Acosta, A., Herman, J. M., Meyer, J., & Narang, A. K. (2022). Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy. Radiation Oncology Journal, 40(2), 111-119. https://doi.org/10.3857/roj.2021.01060

Vancouver

Reddy AV, Hill CS, Sehgal S, Zheng L, He J, Laheru DA, et al. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy. Radiation Oncology Journal. 2022;40(2):111-119. doi:10.3857/roj.2021.01060

BibTeX
@article{Reddy2022,
  author = {Reddy, Abhinav V and Hill, Colin S and Sehgal, Shuchi and Zheng, Lei and He, Jin and Laheru, Daniel A and Jesus-Acosta, Ana De and Herman, Joseph M and Meyer, Jeffrey and Narang, Amol K},
  title = {Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy},
  journal = {Radiation Oncology Journal},
  year = {2022},
  volume = {40},
  number = {2},
  pages = {111--119},
  doi = {10.3857/roj.2021.01060}
}
Kostenlos starten →